Mural im La Mission District San Francisco (Aufnahme Oncoletter)

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Für eine vollständige Ansicht aller 30 Abstract-Titel nutzen Sie bitte die Desktop-Version von Oncoletter

Link to Abstracts

Link to Posters: Sie müssen bei ASCO-GI eingeloggt sein und über eine aktuelle Registrierung verfügen, um auf die Poster dieser Sitzung zugreifen zu können. Hier können Sie die Registrierung erwerben.

  • FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.
  • Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy.
  • Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC.
  • First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.
  • An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
  • A phase 1b/2 study to evaluate the safety and efficacy of TTI‑101 as monotherapy and in combination in advanced hepatocellular carcinoma.
  • Lenvatinib in recurrent hepatocellular carcinoma after liver transplantation.
  • Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
  • FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
  • Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
  • A phase II study to evaluate the safety and efficacy of anlotinib combined with penpulimab for advanced refractory biliary tract cancer.
  • ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.
  • Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
  • PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2.
  • Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma.
  • A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
  • Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
  • Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.
  • Epidemiological characteristics of gastric and pancreatic cancers in Latin America: The LACOG 0222 GASPAR study.
  • DIsCOvER: A multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with locally advanced or metastatic pancreas cancer during first-line chemotherapy.
  • A phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.
  • A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).
  • AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection.
  • A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.
  • COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in adults with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC) and colorectal cancer (CRC) with activating KRAS mutations.
  • A phase II telemedicine study of pemigatinib in adult patients with unresectable or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations.
  • PANOVA-4 (EF-39): Pilot study of tumor treating fields (TTFields) therapy with atezolizumab, gemcitabine (GEM), and nab-paclitaxel (NabP) as first-line (1L) treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).
  • A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
  • AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma.
  • Multicenter study of circulating tumor DNA in patients with pancreatic cancer using a personalized panel: ARTEMIS-PC prospective observational trial.

Presenter: Teresa Macarulla, MD, PhD | Department of Medical Oncology, Vall d´Hebrón University Hospital, Vall d´Hebrón Institute of Oncology (VHIO)

TPS572 FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Mari Nakazawa, MD, MHS | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Presenter: Lorenza Rimassa, MD | Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospit

TPS574 Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Milind M. Javle, MD | Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center

TPS575 First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Farshid Dayyani, MD, PhD | Division of Hematology/Oncology, Department of Medicine, University of California, Irvine

TPS577 A phase 1b/2 study to evaluate the safety and efficacy of TTI‑101 as monotherapy and in combination in advanced hepatocellular carcinoma.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Mehmet Akce, MD | Division of Hematology/Oncology, University of Alabama at Birmingham

TPS578 Lenvatinib in recurrent hepatocellular carcinoma after liver transplantation.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Gong-Rang Chen | Yiyang Central Hospital

TPS579 Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.

 

Für Hintergrund und Methoden siehe Abstract

FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and o

Presenter: Raed Moh'd Taiseer Al-Rajabi, MD | University of Kansas Cancer Center

TPS581 Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Xiaojun He | General Surgery Department, The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital

Presenter: Thorsten Goetze, Prof. Dr. | Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center & Frankfurter IKF

TPS583 ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Stacey Stein, MD | Yale Cancer Center

TPS584 Atezolizumab and bevacizumabin combination with TACE for patients with BCLC B HCC.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Dustin A. Deming, MD | University of Wisconsin Carbone Cancer Center

Presenter: Olivia Aranha, MD, PhD | Washington University School of Medicine in St. Louis

TPS587 A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Michael J. Demeure, MD, MBA | Hoag Memorial Hospital Presbyterian, Translational Genomics Research Institute

Presenter: Renata D'Alpino Peixoto, MD | Grupo Oncoclínicas

Presenter: Bailey Hilty, MD | University of Rochester Cancer Center & Wilmot Cancer Institute

Presenter: Peter Joel Hosein, MD | University of Miami Sylvester Comprehensive Cancer Center

TPS713 A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Brian Hemendra Ramnaraign, MD | University of Florida/UF Health Cancer Center

TPS715 A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Zachary Risch, MD | The Ohio State University

TPS717 A phase II telemedicine study of pemigatinib in adult patients with unresectable or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations.

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Anup Kasi, MD, MPH | University of Kansas Cancer Center

TPS719 A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).

 

Für Hintergrund und Methoden siehe Abstract

Presenter: Edward D. Esplin, MD, PhD, FACP, FACMG | Invitae

TPS721 Multicenter study of circulating tumor DNA in patients with pancreatic cancer using a personalized panel: ARTEMIS-PC prospective observational trial.

 

Für Hintergrund und Methoden siehe Abstract

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2024. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close